FDA approves first generic radioligand therapy for neuroendocrine tumors as Sionna announces major layoffs

The U.S. Food and Drug Administration has cleared Bexlutry, the first generic version of Novartis’ Lutathera, marking the debut of a radioligand therapy that can be used for SSTR‑positive neuroendocrine cancers.

The clearance follows Curium’s victory in a patent dispute with Novartis, opening the market for a lower‑cost option in treating foregut, midgut and hindgut tumors.

At the same time, Sionna Therapeutics said it will lay off roughly half of its workforce and revise its clinical development strategy after a key cystic fibrosis trial failed to meet expectations.

The roundup also noted Novo Nordisk’s rebranding and early promise from a novel RNAi candidate, but the FDA approval and Sionna’s layoffs dominate the headlines.